Pharmaceutical

Hixson is offering a free webinar at 2:00 PM EDT on May 14, 2020. "Optimizing Your Lab Facility: Removing Roadblocks to Success" will enable facilities planning and management professionals to learn how to identify barriers to R&D lab performance; discover design and engineering solutions that can reduce or eliminate lab constraints; and develop a winning business case to make strategic capital investments for facility improvements.

Many existing lab spaces are filled with roadblocks that cause them to be less than ideal: 

E4H Architecture presented a webinar on modular facilities for accelerating vaccine development on May 8, 2020. Now available as an on-demand recording, the exciting session is led by Jeff Schantz, Director of Health Sciences and Technology at E4H. Jeff reviews planning strategies for adapting multi-therapeutic cGMP/BSL-3 cleanroom modules for SARS-CoV-2 response and cell therapy development. Presentation topics include regulatory guidelines, HVAC requirements, design and flow considerations, and decontamination strategies.

Exicure, a clinical-stage biotechnology firm, has leased 30,000 sf in The Labs in Chicago. Accommodating headquarters and research operations relocated from Skokie, Ill., the facility will accelerate the creation of innovative therapies for genetic disorders, inflammatory diseases, and cancer. 

The Vaccines Manufacturing Innovation Centre (VIMC) is being constructed on an accelerated schedule in Oxford in the United Kingdom. Ground was broken on the £66 million project in April of 2020 and occupancy is expected in 2021, a year earlier than previously planned.

The Human Technopole Foundation is planning to construct a 592,000-sf biomedical research campus in the MIND Milano Innovation District in Italy. Designed by Piuarch, the Human Technopole Campus will include a ten-story, 377,000-sf facility offering 177,000 sf of dedicated laboratory space. Comprising two flexible volumes connected by a full-height atrium, the $102 million building will include advanced instrumentation suites, 800 investigator workstations, meeting rooms, event venues, and space for several research centers.

Novo Nordisk completed a $5.1 million tenant renovation and expansion project in March of 2020 in Fremont, Calif. In just four months, MAI Construction remodeled the subleased 44,000-sf facility to provide Asterias Biotherapeutics with leading-edge research, production, and office spaces to support the creation of innovative stem cell therapies. The four-phase project included the construction of new cGMP Grade B manufacturing labs, as well as a materials lift and canopy for the area's shipping and receiving area.

The International Society for Pharmaceutical Engineering has announced the 2020 Facility of the Year Awards category winners. The awards include:

Federal financial measures have been approved in the past few weeks to shore up the economy during the COVID-19 pandemic, with direct monetary assistance and business loans totaling $5.5 trillion, and more support and flexibility for research universities and government contractors. The federal stimulus package—the Coronavirus Aid, Relief, and Economic Security (CARES) Act—is intended to pump $2.2 trillion dollars into the economy, primarily in the healthcare and research sectors, and to provide emergency relief to institutions, businesses, and workers whose livelihoods have been impacted by the pandemic. The specifics of how it will be implemented are still evolving, and it is likely that additional stimulus bills will be considered in the coming months, including investments in infrastructure for the nation’s research enterprise.

VACUUBRAND is offering continuing education courses approved by the American Institute of Architects and Green Business Certification Inc. Providing engineers and designers with the skills to create sustainable, high-performance laboratories, each course is available as a general webinar, a private webinar, or as an on-demand learning experience. AIA members will receive one LU/HSW (Health-Safety-Welfare learning unit) for each one-hour course.

Regeneron Pharmaceuticals is constructing an $800 million manufacturing campus in East Greenbush, N.Y. The complex is now in the third and final phase of development, which includes an $188 million, 346,000-sf production facility; a 240,000-sf lab and office building; and a six-story, 1,050-space parking garage. BBL Construction Services is managing the project with completion expected by 2022.

A $2.2 trillion stimulus package will support the National Institutes of Health and the Centers for Disease Control and Prevention in their response to the SARS-CoV-2 pandemic. Funding from the Coronavirus Aid, Relief, and Economic Security Act (CARES) will be available to the agencies through September of 2024. The CDC will receive $4.3 billion in new funding, which includes $1.5 billion for joint initiatives with state and local governments. The NIH has been allocated $945.4 million, which will be directed to:

Vermeulens has released its market outlook report for the fourth quarter of 2019. Key points include:

Amicus Therapeutics opened the $25 million Global Research and Gene Therapy Center of Excellence in March of 2020 in Philadelphia. Accommodating up to 200 employees, the 75,000-sf project provides collaborative labs and offices to support the discovery and development of new therapies for rare metabolic diseases.

Audentes Therapeutics is planning to construct a $109 million gene therapy manufacturing facility in Sanford, N.C. The 135,000-sf project will support the production of genetic medicines based on adeno-associated virus vectors for the treatment of rare neuromuscular diseases. The center is expected to be operational by 2021. Audentes Therapeutics is a subsidiary of Astellas Pharma.

Athenex is constructing a $210 million pharmaceutical plant in Dunkirk, N.Y. Supporting the production of advanced cancer therapies, the 409,000-sf complex will provide research, office, manufacturing, and warehouse space. General contractor Exyte broke ground on the facility in May of 2018, and commercial operations will commence at the site in early 2022. The project is part of a strategic infrastructure development plan to enable Athenex to offer vertically integrated oncology services from discovery through marketing.